Table 1.

Multivariate analyses of the sorafenib, placebo, and all-patient cohorts to identify factors independently prognostic for OS in patients with HCC

Placebo cohortSorafenib cohortAll-patient cohort
Baseline factorP valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)
Treatment (sorafenib vs. placebo)NANA0.0410.78 (0.61–0.99)
ECOG PS (0 vs. >0)NSNS0.0161.36 (1.06–1.75)
AFP (≤ vs. >200 ng/mL)0.0071.58 (1.13–2.21)0.0151.57 (1.09–2.26)0.0011.49 (1.17–1.89)
MVI (present vs. absent)0.00031.88 (1.34–2.66)0.0051.74 (1.19–2.55)<0.00011.81 (1.43–2.32)
EHS (present vs. absent)NS0.0161.60 (1.09–2.34)NS
Alkaline phosphatase (≤ vs. >median)0.0131.56 (1.10–2.22)0.0021.82 (1.26–2.63)0.00031.59 (1.24–2.04)
s-c-KIT (≤ vs. >11.3 ng/mL)NS0.0040.56 (0.38–0.83)NS
HGF (≤ vs. >3,279.1 pg/mL)NS0.0171.69 (1.10–2.60)NS
VEGF (≤ vs. >101.9 pg/mL)0.0021.97 (1.28–3.04)NS0.0151.48 (1.08–2.03)
Ang2 (≤ vs. >6,043.5 pg/mL)0.0021.84 (1.25–2.70)0.0341.59 (1.04–2.43)0.0011.58 (1.20–2.07)

NOTE: Analyses included the following baseline variables: all biomarker values, ECOG PS, AFP, macroscopic vascular invasion (MVI), extrahepatic spread (EHS), albumin score, alkaline phosphatase, bilirubin score, prothrombin time, presence of ascites, and, for the all-patient cohort analysis, treatment group. Factors with P < 0.05 in one or more of the analyses are shown.

Abbreviations: NA, not applicable; NS, not significant (P > 0.05).